Neuronetics, Inc. is a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. We are the first company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients suffering from depression who have not achieved satisfactory improvement from prior antidepressant medication*. Based in Malvern, PA, we are the market leader in TMS Therapy with the development of the NeuroStar TMS Therapy® System, a non-invasive form of neuromodulation.
Incorporated in 2003, we began by licensing a revolutionary patented coil design from Emory University. Using this new, more efficient coil, our first TMS Therapy research units were built and used to complete the largest clinical trial ever conducted (23 international sites) evaluating TMS Therapy, using the NeuroStar System in the treatment of major depression.
Since completing clinical trials, our experienced Product Development group has continued to refine our early research device to develop a high quality, efficient, user friendly commercial unit – the NeuroStar TMS Therapy® System.
In October of 2008, the NeuroStar TMS Therapy System received FDA clearance for the treatment of major depressive disorder in patients suffering from depression who have not achieved satisfactory improvement from prior antidepressant medication*. NeuroStar TMS Therapy is available by prescription.
Our goal moving forward is to partner with healthcare professionals by providing them the best products and services possible. We are committed to continuous product improvement and to developing new and innovative solutions to meet our customers’ needs. By providing these tools, we can help healthcare professionals achieve their ultimate goal of effectively treating the patients they serve.
All trademarks are the property of Neuronetics, Inc.
*NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical trial version of the NeuroStar TMS System, were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05)1
The most common side effect is pain or discomfort at or near the treatment site.2 These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. NeuroStar TMS Therapy is contraindicated in patients with non-removable conductive metal in or near the head.
NeuroStar TMS Therapy is available by prescription only. For full prescribing and safety information, please visit www.NeuroStar.com or call Neuronetics Customer Service at 1-877-600-7555.
1) George, MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder A Sham-Controlled Randomized Trial. Arch Gen Psychiatry. 67(5): 507-516.
2) Janicak, PG, et al. (2008) Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Comprehensive Summary of Safety Experience from Acute and Extended Exposure and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.